within Pharmacolibrary.Drugs.ATC.N;

model N07BC51
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.3,
    Cl             = 0.0009683333333333333,
    adminDuration  = 600,
    adminMass      = 8 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.223,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0014,
    Tlag           = 300,            
    Vdp             = 0.592,
    k12             = 58.4,
    k21             = 58.4
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N07BC51</td></tr><td>route:</td><td>sublingual</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Buprenorphine, in combination with naloxone, is a partial opioid agonist medication primarily used for the treatment of opioid dependence and opioid use disorder. The combination is an approved and widely used pharmacotherapy to reduce withdrawal symptoms and cravings and is designed to reduce misuse potential of buprenorphine alone.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetics in adult opioid-dependent patients (males and females, aged 18-65 years), typical for sublingual tablet co-formulation buprenorphine/naloxone.</p><h4>References</h4><ol><li><p>Gu, M, et al., &amp; Zhu, X (2023). Population pharmacokinetics of buprenorphine and naloxone sublingual combination in Chinese healthy volunteers and patients with opioid use disorder: Model-based dose optimization. <i>Frontiers in pharmacology</i> 14 1089862–None. DOI:<a href=&quot;https://doi.org/10.3389/fphar.2023.1089862&quot;>10.3389/fphar.2023.1089862</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36744255/&quot;>https://pubmed.ncbi.nlm.nih.gov/36744255</a></p></li><li><p>Chiang, CN, &amp; Hawks, RL (2003). Pharmacokinetics of the combination tablet of buprenorphine and naloxone. <i>Drug and alcohol dependence</i> 70(2 Suppl) S39–S47. DOI:<a href=&quot;https://doi.org/10.1016/s0376-8716(03)00058-9&quot;>10.1016/s0376-8716(03)00058-9</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/12738349/&quot;>https://pubmed.ncbi.nlm.nih.gov/12738349</a></p></li><li><p>Harris, DS, et al., &amp; Jones, RT (2004). Pharmacokinetics and subjective effects of sublingual buprenorphine, alone or in combination with naloxone: lack of dose proportionality. <i>Clinical pharmacokinetics</i> 43(5) 329–340. DOI:<a href=&quot;https://doi.org/10.2165/00003088-200443050-00005&quot;>10.2165/00003088-200443050-00005</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/15080765/&quot;>https://pubmed.ncbi.nlm.nih.gov/15080765</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N07BC51;
